No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
KRYS Krystal Biotech
- 156.880
- +1.200+0.77%
Close Apr 26 16:00 ET
- 159.970
- +3.090+1.97%
Post 16:20 ET
4.47BMarket Cap402.26P/E (TTM)
158.930High153.790Low165.90KVolume156.280Open155.680Pre Close25.96MTurnover0.80%Turnover Ratio402.26P/E (Static)28.51MShares189.97052wk High5.75P/B3.25BFloat Cap82.09052wk Low--Dividend TTM20.71MShs Float189.970Historical High--Div YieldTTM3.30%Amplitude8.030Historical Low156.462Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024
PITTSBURGH, April 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter 2024 financial results
Express News | HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $200 Price Target
Express News | Krystal Biotech Has Dosed The First Patient In Its Phase 1 Clinical Trial (KYANITE-1) Evaluating Inhaled KB707 For Locally Advanced Or Metastatic Solid Tumors Of The Lung
Express News | Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung
Krystal Biotech Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/16/2024 23.64% Stifel $178 → $204 Reiterates Buy → Buy 02/27/2024 18.18% Citigroup $160 → $195 Maintain
Express News | Krystal Biotech Inc : Stifel Raises Target Price to $204 From $178
Comments
The strong revenue growth is mirrored in the share price gain. Despite the strong run, top performers like Krystal Biotech can continue winning for decades. The stock's recent performance improvement may suggest real business momentum.
Investing in Krystal Biotech (NASDAQ:KRYS) Five Years Ago Would Have Delivered You a 389% Gain 1
High insider ownership at Krystal Biotech implies management's alignment with shareholders. Yet, no insider transactions in the last three months and significant share selling over the past year are concerning.
Analysts' optimism soars as they forecast Krystal Biotech to break even soon, given its massive projected annual growth rate of 68%. The firm's debt-free operation, unusual in loss-making biotech companies, lowers investment risk.
Market rewards Krystal Biotech's significant revenue growth despite recent stock price decline. Bullish sentiment suggests ongoing positive trend, irrespective of the current drop.
Despite the substantial selling of shares over the past year, insiders' ownership is still considerable. However, the lack of recent insider purchases could be of concern. Investors are advised to also consider the potential risks facing Krystal Biotech.
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg